Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Neolys Diagnostics

Neolys Diagnostics_logo
25
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Neolys Diagnostics offers the first ever tests that determine the patient’s radiosensitivity for a personalized, better tolerated and more efficient radiotherapy. These tests represent substantial awaited innovation from the practitioners.

Lyon, Auvergne-Rhône-Alpes, France

Send a message

Anglais

Neolys Diagnostics

Anglais

Neolys Diagnostics offers the first ever tests that determine the patient’s radiosensitivity for a personalized, better tolerated and more efficient radiotherapy. These tests represent substantial awaited innovation from the practitioners.

Neolys Diagnostics proposes to the radio-oncologists a comprehensive solution to define the radiosensitivity for each patient:

1 RadioDTect –

See more

Neolys Diagnostics offers the first ever tests that determine the patient’s radiosensitivity for a personalized, better tolerated and more efficient radiotherapy. These tests represent substantial awaited innovation from the practitioners.

Neolys Diagnostics proposes to the radio-oncologists a comprehensive solution to define the radiosensitivity for each patient:

1 RadioDTect – screening test (CE marking Q2 2018) to identify patient at risk (ELISA test done at the cancer care center);

2 RadioProfile – complete test (CE marked) to precisely characterize the radiosensitivity of such patients (Immunofluorescence assay on 2mm² of skin transferred at room temperature to a specialized medical lab);

3 – decision support software (collection of radiosensitivity, dosimetry and comorbidity data).

Engaged in several clinical trials in Europe (Head & Neck cancer; prostate cancer and pediatric cancer), Neolys Diagnostics’ technology is protected by 7 patents, a secret algorithm and a the largest proprietary database.

The targeted potential market represents more than 2 billion€/year with first focus on Head & Neck, prostate and pediatric cancers.  Early sales are expected in 2018 in the EU and the first reimbursement by 2021.

Neolys Diagnostics has mobilized more than 2M€ (non-dilutive) and has raised 1,3M€ in 2 seed rounds. A 2M€ round A will be raised in 2018 to finance the industrialization, the regulatory approval of the ELISA test and the first sales.

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

EUREKA Accelerated
Eureka is the world’s leading network for international R&D collaborations, represented in over 45 countries. It aims to boost the growth of SMEs, large companies, research organisations and universities through funding and supporting international R&D cooperation and providing investment-readiness services Through Eureka’s programmes, organisations can access funding and expert support. The Eureka label is given to companies who have been financed through Eureka programmes.
212 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1920 Members
Les Deeptech
Les Deeptech, c’est la communauté qui rassemble les startups deeptech françaises et les investisseurs désirant développer des relations business avec elles.
253 Members
SATT
SATTs are Societies By Simplified Actions created by several public research centers as part of the "Investments for the Future" Program (french PIA); within the commercialization department.
278 Members

Our history

Start in July 2017

  • July 2017

    A breakthrough innovation: a fast & efficient blood test for radiosensitivity before radiotherapy.

  • Jan 2017

    EUROSTAR granted to develop a complete solution Software+Biological Test to handle Radiosensitivity

  • June 2016

    Neolys Diagnostics has raised 660k€ in a seed round from BA and Wiseed

  • August 2015

    Pulsalys becomes a shareholder of Neolys Diagnostics.

  • November 2015

    Neolys Diagnostics has been awarded with R2B ONCO 2015 trophy.

to be continued ...